Feb 28, 2024 4:05pm EST Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
Feb 07, 2024 7:55am EST Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
Jan 29, 2024 9:05am EST Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
Jan 16, 2024 4:05pm EST Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
Dec 19, 2023 8:30am EST Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
Nov 14, 2023 4:30pm EST Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity
Nov 07, 2023 9:28am EST Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023
Nov 07, 2023 8:00am EST Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023
Oct 16, 2023 7:00am EDT Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment